Bispecific/Multispecific Ab Discovery Platforms

Other BsAb and MsAb platforms from WuXi Biologics

WuXi Biologics offers expertise and additional technology platforms beyond WuXiBody and SDArBody for the development of bispecific antibodies (bsAbs) and multispecific antibodies(msAbs). Our other platforms includes scFv and transgenic hybridoma approaches as well as experience with many technologies readily available in the public domain. To learn more, please visit: wuxibiologics.com/discovery/bispecific-antibody

WuXi Biologics General Platform

Transgenic Rats with Common Light Chain

• Extensive engineering provides more stable scFv • SKYBody bsAbs and msAbs demonstrate good developability characteristics Proprietary platform for bsAbs generated using scFv

• Experience with 100+ formats available in the public domain • Engineering of bsAbs and msAbs using scFab and scFv • Optimize molecules to improve developability while maintaining antigen-binding

• Fully human antibody repertoire using transgenic rodents • Generates antibodies with common light chain –ideal for bsAb development

Integrated End-To-End Discovery Services

What makes WuXi Biologics unique is our integrated, one-stop biologics discovery and development service platform from target to IND. Our comprehensive single-source services reduce risk and save significant time by incorporating developability assessment into the discovery activities. To learn more about our integrated discovery services, please visit: wuxibiologics.com/discovery

DISCOVERY

CMC DEVELOPMENT

Target (Concept) Target Evaluation Reagent Material Generation

Lead Optimization & Characterization Optimization (e.g., humanization, affinity maturation, Fc engineering) In vitro characterization (e.g., binding, epitope binning & mapping, functional assays) In vivo characterization (e.g., PK/PD, tox, efficacy, tumor models, ex vivo studies)

Antibody Discovery Monoclonal, bispecific & multispecific antibody engineering, generation and screening Hybridoma (including transgenic), phage display, VHH immune libraries and single cell B cloning platforms Other molecule modalities (antibody fragments, fusion proteins, ADCs etc.)

IND Filing Support Clinical development plan/ protocols & registration support Pre-IND meeting, CMC Dossier preparation, & regulatory affairs consultation

About WuXi Biologics

WuXi Biologics is a leading contract research, development and manufacturing organization (CRDMO) that provides end-to-end capabilities to healthcare organizations worldwide. With operations in China, the United States, Ireland, Germany, and Singapore, we enable our partners to effectively and efficiently bring biologics and vaccines to patients worldwide through our comprehensive and high-quality drug development model.

wuxibiologics.com | info@wuxibiologics.com The world’s leading global single-source platform from concept to commercialization.

11-21-2023

Powered by